pS2-A new cytosolic protein recognized by monoclonal antibodies as a marker of hormone sensitivity in breast cancer

M. Correale, I. Abbate, A. Paradiso, F. Schittulli, C. D. Dragone, T. Tedone, G. Gargano, A. M. Catino, M. D. Musci, M. De Lena

Research output: Contribution to journalArticlepeer-review

Abstract

Using a new immunoradiometric assay (ELSA pS2 Cis-France), a total of 200 cytosols obtained from primary breast tumors were examined for pS2 content, which is an estrogen-regulated protein actually studied as a marker of hormone sensitivity and favorable prognostic factor in breast cancer. In our patient group, the median pS2 value corresponding to 5.3 ng/mg of cytosolic proteins was used as cutoff. pS2 content was not related to menopause status, tumor size, or nodal involvement, whereas a positive correlation was found between pS2 and ER/PgR status. Moreover, the association of pS2 with steroid receptors seems to identify subgroups of patients better than ER/PgR alone.

Original languageEnglish
Pages (from-to)101-110
Number of pages10
JournalCell Biophysics
Volume22
Issue number1-3
DOIs
Publication statusPublished - Jan 1993

Keywords

  • Breast cancer
  • hormone sensitivity
  • pS2

ASJC Scopus subject areas

  • Cell Biology
  • Biophysics

Fingerprint

Dive into the research topics of 'pS2-A new cytosolic protein recognized by monoclonal antibodies as a marker of hormone sensitivity in breast cancer'. Together they form a unique fingerprint.

Cite this